MediWound (NASDAQ:MDWD) COO Shmuel Hess Sells 3,958 Shares

MediWound Ltd. (NASDAQ:MDWD) COO Shmuel Hess sold 3,958 shares of the company’s stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $12.92, for a total transaction of $51,137.36. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Shmuel Hess also recently made the following trade(s):

• On Wednesday, August 26th, Shmuel Hess sold 1,865 shares of MediWound stock. The shares were sold at an average price of $13.00, for a total transaction of $24,245.00.

MediWound Price Performance

MDWD stock traded down $0.58 during trading on Friday, hitting $12.66. The stock had a trading volume of 165,534 shares, compared to its average volume of 92,786. MediWound Ltd. has a twelve month low of $12.52 and a twelve month high of $20.30. The company’s 50-day moving average price is $14.19 and its two-hundred day moving average price is $15.66. The stock has a market capitalization of $162.71 million, a P/E ratio of -7.03 and a beta of 0.15.

MediWound (NASDAQ:MDWD) last announced its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.01). The firm had revenue of $3.09 million for the quarter, compared to analyst estimates of $2.59 million. MediWound had a negative net margin of 170.10% and a negative return on equity of 47.24%. As a group, sell-side analysts expect that MediWound Ltd. will post -2.31 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on MDWD. HC Wainwright reaffirmed a “buy” rating and set a $36.00 target price on shares of MediWound in a research note on Thursday, May 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of MediWound in a research note on Friday, July 17th. Oppenheimer restated an “outperform” rating and set a $30.00 price target (down from $32.00) on shares of MediWound in a research report on Friday, August 14th. Finally, Wall Street Zen cut shares of MediWound from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $33.00.

Institutional Trading of MediWound

Large investors have recently added to or reduced their stakes in the stock. Quarry LP purchased a new position in shares of MediWound during the 4th quarter worth $26,000. BNP Paribas Financial Markets increased its position in MediWound by 90.4% during the third quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 723 shares during the last quarter. California State Teachers Retirement System increased its position in MediWound by 281.4% during the second quarter. California State Teachers Retirement System now owns 2,014 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 1,486 shares during the last quarter. Russell Investments Group Ltd. raised its stake in MediWound by 69.1% during the second quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 649 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in MediWound by 22.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 999 shares during the period. 46.83% of the stock is currently owned by hedge funds and other institutional investors.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.